Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs S&P Global Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while S&P Global Inc trades at $411.5 (market cap $120.45B). The key difference: S&P Global Inc is far larger — about 13.6× Kymera Therapeutics Inc. Common Stock's market cap, and S&P Global Inc pays a 0.95% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and S&P Global Inc for 124 Days on average.
| KYMR | SPGI | |
|---|---|---|
Market Cap | $8.87B | $120.45B |
Volume | 779,107 | 1,198,667 |
Sector | Health | Financials |
52-Week High | $127.31 | $517.92 |
52-Week Low | $55.80 | $370.42 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $8.26B | $131.93B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPGI trades at $409.99, down 0.53% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong revenue growth to $15.34 billion in 2025, with net income reaching $4.47 billion and a robust net margin of 30.54%. Recent developments include the acquisition of OpenZeppelin and the launch of new risk assessment services, expanding its market intelligence offerings.
The outlook remains positive with analyst consensus strongly bullish, an average price target of $509.50 implying significant upside. Risks include high valuation multiples and exposure to economic cycles, but sustained profitability and strategic expansions support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
